Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Theliatinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 29 Sep 2017 Results presented in a Chi-Med media release.
- 29 Sep 2017 According to a Chi-Med media release, results were presented at the Chinese Society of Clinical Oncology (CSCO) 2017.
- 13 Jan 2017 Planned number of patients changed from 18 to 66.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History